Profiling estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2/neu in breast carcinoma: Study of 111 consecutive cases

Abstract

Background: Breast cancer is a major health problem for women throughout the world representing nearly a quarter (25%) of all cancers with an estimated 1.67 million new cancer cases diagnosed in 2012. In India, breast cancer is second only to cancer of the cervix among women. It is considered to the be the leading cancer in some cities such as Mumbai and Bangalore. The present study analyzed the pattern of expression of hormone receptor Estrogen receptor (ER), progesterone receptor (PR), and Her-2/neu in invasive breast carcinoma. Materials and Methods: The data for the present study were retrieved from a hospital-based registry of breast cancer established in the department of radiotherapy of a tertiary care center in rural area of North-West India. Records of 111 consecutive patients extending from October 2015 to September 2017 were profiled. Results: One hundred and ten cases were invasive breast carcinoma, not otherwise specify (IDC-NOS). Age of the patients ranged from 30 to 74 years with median age of 48 years. Approximately half of the patients were postmenopausal (n = 58, 52.2%) and left side breast carcinoma was more common (n = 60, 54.1%). Most of the cases belonged to Grade II (n = 60, 54.1%), followed by Grade III (n = 34, 30.6%) with 60 (54.1%) and 48 (43.2%) of cases found in Stage III and II, respectively. ER, PR, human epidermal growth factor receptor 2 (HER2/neu) positive, and triple negative expression were seen in 59 (53.2%), 50 (45.0%), 37 (33.3%), and 31 (27.9%), respectively. Conclusions: Older patients (>50 years) showed higher positivity of ER/PR/HER2 as compared to younger age group, while triple negativity was higher in younger age group.